RU2552169C3 - Высокоаффинные человеческие антитела к pcsk9 - Google Patents
Высокоаффинные человеческие антитела к pcsk9 Download PDFInfo
- Publication number
- RU2552169C3 RU2552169C3 RU2011129316A RU2011129316A RU2552169C3 RU 2552169 C3 RU2552169 C3 RU 2552169C3 RU 2011129316 A RU2011129316 A RU 2011129316A RU 2011129316 A RU2011129316 A RU 2011129316A RU 2552169 C3 RU2552169 C3 RU 2552169C3
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- pcsk9
- binding fragment
- antigen
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
Claims (3)
1. Антитело человека или антигенсвязывающий фрагмент антитела человека, который специфическим образом связывает человеческую пропротеинконвертазу субтилизин/кексин тип 9 («hPCSK9»), где антитело или антигенсвязывающий фрагмент содержит CDR последовательности тяжелой и легкой цепи, представленные последовательностями SEQ ID NO: 76, 78, 80, 84, 86, 88.
2. Антитело или антигенсвязывающий фрагмент по п. 1, содержащее пару аминокислотных последовательностей вариабельной области тяжелой цепи/вариабельной области легкой цепи (HCVR/LCVR), представленной последовательностями SEQ ID NO: 90/92.
3. Фармацевтический состав для лечения заболевания или состояния, которое поддается смягчению, улучшению, подавлению или предотвращению с помощью антагониста PCSK9, включающий антитело или антигенсвязывающий фрагмент по п. 1 или 2 в терапевтически эффективном количестве и фармацевтически приемлемый носитель, где опосредованное PCSK9 заболевание или состояние выбрано из группы, состоящей из гиперхолестеринемии, гетерозиготной наследственной гиперхолестеринемии и дислипидемии.
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12248208P | 2008-12-15 | 2008-12-15 | |
| US61/122,482 | 2008-12-15 | ||
| US21056609P | 2009-03-18 | 2009-03-18 | |
| US61/210,566 | 2009-03-18 | ||
| US16875309P | 2009-04-13 | 2009-04-13 | |
| US61/168,753 | 2009-04-13 | ||
| US21813609P | 2009-06-18 | 2009-06-18 | |
| US61/218,136 | 2009-06-18 | ||
| US24913509P | 2009-10-06 | 2009-10-06 | |
| US61/249,135 | 2009-10-06 | ||
| US26177609P | 2009-11-17 | 2009-11-17 | |
| US61/261,776 | 2009-11-17 | ||
| PCT/US2009/068013 WO2010077854A1 (en) | 2008-12-15 | 2009-12-15 | High affinity human antibodies to pcsk9 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015109166A Division RU2697773C2 (ru) | 2008-12-15 | 2009-12-15 | Высокоаффинные человеческие антитела к pcsk9 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2011129316A RU2011129316A (ru) | 2013-01-20 |
| RU2552169C2 RU2552169C2 (ru) | 2015-06-10 |
| RU2552169C3 true RU2552169C3 (ru) | 2018-01-19 |
Family
ID=41668268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011129316A RU2552169C3 (ru) | 2008-12-15 | 2009-12-15 | Высокоаффинные человеческие антитела к pcsk9 |
| RU2015109166A RU2697773C2 (ru) | 2008-12-15 | 2009-12-15 | Высокоаффинные человеческие антитела к pcsk9 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015109166A RU2697773C2 (ru) | 2008-12-15 | 2009-12-15 | Высокоаффинные человеческие антитела к pcsk9 |
Country Status (44)
Families Citing this family (274)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9889197B2 (en) * | 2005-04-15 | 2018-02-13 | Macrogenics, Inc. | Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US20130072665A1 (en) * | 2007-08-23 | 2013-03-21 | Simon Mark Jackson | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| MX2011014008A (es) | 2009-06-26 | 2012-06-01 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| DK3241435T3 (da) | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| CN102639150A (zh) | 2009-10-30 | 2012-08-15 | 默沙东公司 | Ax213和ax132 pcsk9拮抗剂和变体 |
| AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| MX2012010481A (es) | 2010-03-11 | 2012-10-09 | Rinat Neuroscience Corp | Anticuerpos con union de antigenos dependiente del ph. |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| WO2012088313A1 (en) * | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
| EP2650016A1 (en) | 2011-01-28 | 2013-10-16 | Sanofi | Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565) |
| EP2481758A1 (en) * | 2011-01-28 | 2012-08-01 | Sanofi | Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566) |
| CN103476796A (zh) * | 2011-01-28 | 2013-12-25 | 赛诺菲 | 治疗特定受试者组的方法中使用的针对pcsk9的人抗体 |
| EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
| US8337530B2 (en) | 2011-03-09 | 2012-12-25 | Zimmer Spine, Inc. | Polyaxial pedicle screw with increased angulation |
| AR088782A1 (es) | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| EP3385280A1 (en) | 2011-06-10 | 2018-10-10 | MedImmune Limited | Anti-pseudomonas psl binding molecules and uses thereof |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| EP2731623A1 (en) * | 2011-07-14 | 2014-05-21 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EP3536712B1 (en) * | 2011-09-16 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
| AR087715A1 (es) * | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| JP5813880B2 (ja) | 2011-09-19 | 2015-11-17 | カイマブ・リミテッド | ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖 |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| ITPC20110013U1 (it) | 2011-10-07 | 2013-04-08 | Giovanni Merli | Struttura di protezione superiore veicoli. |
| RS60920B1 (sr) | 2011-11-07 | 2020-11-30 | Medimmune Ltd | Kombinovane terapije primenom anti-pseudomonas psl i pcrv vezujućih molekula |
| WO2013081143A1 (ja) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬 |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| US20150284471A1 (en) | 2011-12-08 | 2015-10-08 | Amgen Inc | Human LCAT Antigen Binding Proteins and Their Use in Therapy |
| EA033387B1 (ru) | 2012-01-23 | 2019-10-31 | Regeneron Pharma | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 |
| ES2707599T3 (es) * | 2012-01-31 | 2019-04-04 | Regeneron Pharma | Anticuerpos anti-asic1 y usos de los mismos |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| EP2883449B1 (en) | 2012-03-16 | 2018-02-07 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
| KR20140134672A (ko) | 2012-03-16 | 2014-11-24 | 리제너론 파마슈티칼스 인코포레이티드 | pH-의존성 결합 특성을 나타내는 항원-결합 단백질을 생성하는 마우스 |
| CN107361011B (zh) | 2012-03-16 | 2021-08-27 | 瑞泽恩制药公司 | 制备表达ph敏感性免疫球蛋白序列的非人动物的方法 |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| US20130281355A1 (en) * | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| EA039663B1 (ru) * | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| CA2875096A1 (en) * | 2012-06-15 | 2013-12-19 | Genentech, Inc. | Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
| AU2013302925B2 (en) | 2012-08-13 | 2018-07-05 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
| JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| BR112015001955A2 (pt) | 2012-08-24 | 2017-11-07 | Chugai Pharmaceutical Co Ltd | variante de região fc específica de fcgamariib |
| EP2703008A1 (en) * | 2012-08-31 | 2014-03-05 | Sanofi | Human antibodies to PCSK9 for use in methods of treating particular groups of subjects |
| EP2703009A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| EP2706070A1 (en) | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| JP2015535464A (ja) | 2012-11-21 | 2015-12-14 | アムジエン・インコーポレーテツド | 薬剤送達装置 |
| ES2876009T3 (es) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Polipéptido heterodimerizado |
| WO2014107657A2 (en) * | 2013-01-04 | 2014-07-10 | Kohn Kenneth I | Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation |
| WO2014107739A1 (en) * | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
| WO2014149699A1 (en) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Bifunctional protein |
| AU2014235430A1 (en) * | 2013-03-15 | 2015-09-24 | Amgen Inc. | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9) |
| EP2968760B1 (en) | 2013-03-15 | 2024-01-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| TWI639449B (zh) | 2013-03-15 | 2018-11-01 | 美商安美基公司 | 用於注射器之匣盒 |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| LT2976117T (lt) | 2013-03-22 | 2021-02-25 | Amgen Inc. | Purkštuvas ir surinkimo būdas |
| WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Ｆｃ領域改変体 |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| EP2810955A1 (en) | 2013-06-07 | 2014-12-10 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| EA201592267A1 (ru) * | 2013-06-07 | 2016-04-29 | Ридженерон Фармасьютикалз, Инк. | Способы ингибирования атеросклероза посредством введения ингибитора pcsk9 |
| EP2862877A1 (en) | 2013-10-18 | 2015-04-22 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| ES2901400T3 (es) * | 2013-06-07 | 2022-03-22 | Regeneron Pharma | Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9 |
| AU2013396206B2 (en) | 2013-06-28 | 2019-11-14 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
| NL2013554B1 (en) | 2013-10-01 | 2016-01-08 | Kymab Ltd | Animal models and therapeutic molecules. |
| US20150140002A1 (en) * | 2013-10-11 | 2015-05-21 | Sanofi | Use of a pcsk9 inhibitor to treat hyperlipidemia |
| EP3501575B1 (en) | 2013-10-24 | 2021-12-01 | Amgen Inc. | Drug delivery system with temperature-sensitive-control |
| EP3789064A1 (en) | 2013-10-24 | 2021-03-10 | Amgen, Inc | Injector and method of assembly |
| TW202017595A (zh) * | 2013-11-12 | 2020-05-16 | 法商賽諾菲生物技術公司 | 使用ｐｃｓｋ９抑制劑之給藥療程 |
| AU2014348765A1 (en) | 2013-11-12 | 2016-06-09 | Regeneron Pharmaceuticals, Inc. | Dosing regimens for use with PCSK9 inhibitors |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| EP3572425A1 (en) * | 2013-12-17 | 2019-11-27 | AIMM Therapeutics B.V. | Means and methods for counteracting myeloproliferative or lymphoproliferative disorders |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| JP2017506626A (ja) | 2014-02-14 | 2017-03-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN114558129A (zh) * | 2014-03-17 | 2022-05-31 | 赛诺菲生物技术公司 | 用于降低心血管风险的方法 |
| CA2945026C (en) | 2014-05-07 | 2023-10-10 | Amgen Inc. | Autoinjector with shock reducing elements |
| ES2913205T3 (es) | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
| CA2948003C (en) | 2014-06-03 | 2023-06-27 | Amgen Inc. | Drug delivery system and method of use |
| WO2015200438A1 (en) * | 2014-06-24 | 2015-12-30 | Eleven Biotherapeutics, Inc. | High affinity antibodies against pcsk9 |
| EP2975059A1 (en) | 2014-07-15 | 2016-01-20 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| DE202015009007U1 (de) | 2014-07-15 | 2016-08-19 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| EP4328245A3 (en) | 2014-07-15 | 2024-06-05 | Kymab Ltd. | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| JP2017528427A (ja) | 2014-07-16 | 2017-09-28 | サノフィ・バイオテクノロジー | ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法 |
| PL3169362T3 (pl) * | 2014-07-16 | 2020-12-28 | Sanofi Biotechnology | Sposoby leczenia pacjentów wysokiego ryzyka sercowo-naczyniowego z hipercholesterolemią |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| EP3193928A1 (en) | 2014-08-06 | 2017-07-26 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
| WO2016020799A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
| WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| KR20170062466A (ko) | 2014-09-16 | 2017-06-07 | 리제너론 파마슈티칼스 인코포레이티드 | 항-글루카곤 항체 및 그것의 사용 |
| US10472424B2 (en) | 2014-09-23 | 2019-11-12 | Pfizer Inc. | Treatment with anti-PCSK9 antibodies |
| MX2021014323A (es) | 2014-10-14 | 2023-02-02 | Amgen Inc | Dispositivo de inyección de fármaco con indicadores visuales y audibles. |
| MX2017005243A (es) | 2014-10-23 | 2017-08-18 | Amgen Inc | Reducción de la viscosidad de formulaciones farmacéuticas. |
| WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
| KR20180054923A (ko) | 2014-12-19 | 2018-05-24 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
| MX2017008978A (es) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos. |
| CN105461809B (zh) * | 2015-02-11 | 2018-10-12 | 康融东方（广东）医药有限公司 | Pcsk9抗体、其药物组合物及其用途 |
| CA2976935C (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| EP3261690B1 (en) | 2015-02-27 | 2021-12-15 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
| EP3271405A1 (en) * | 2015-03-20 | 2018-01-24 | Aarhus Universitet | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders |
| US10787516B2 (en) | 2015-05-18 | 2020-09-29 | Agensys, Inc. | Antibodies that bind to AXL proteins |
| EP3297663A4 (en) | 2015-05-18 | 2018-12-19 | Agensys, Inc. | Antibodies that bind to axl proteins |
| CN106084058B (zh) * | 2015-07-15 | 2019-08-27 | 北京天广实生物技术股份有限公司 | 抗人pcsk9单克隆抗体 |
| TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CN107922507B (zh) | 2015-08-18 | 2022-04-05 | 瑞泽恩制药公司 | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
| CN105348390B (zh) * | 2015-10-26 | 2018-08-28 | 北京智仁美博生物科技有限公司 | 抗人pcsk9单克隆抗体 |
| CN106810609A (zh) * | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
| JP7082568B2 (ja) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | 信号伝達キャップ付き自動注射器 |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| MX2018007925A (es) * | 2015-12-31 | 2018-08-29 | Jiangsu Hengrui Medicine Co | Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo. |
| US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
| HRP20230992T1 (hr) * | 2016-02-17 | 2023-12-08 | Regeneron Pharmaceuticals, Inc. | Postupci za liječenje ili sprečavanje ateroskleroze davanjem inhibitora angptl3 |
| AU2017227713B2 (en) | 2016-03-03 | 2022-12-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor |
| WO2017160799A1 (en) | 2016-03-15 | 2017-09-21 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| WO2017163049A1 (en) | 2016-03-21 | 2017-09-28 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
| US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
| CN107266575B (zh) * | 2016-04-07 | 2021-12-24 | 天士力生物医药股份有限公司 | 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用 |
| US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| WO2017197222A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
| EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| CN107474140B (zh) | 2016-06-08 | 2022-06-03 | 常州博嘉生物医药科技有限公司 | Pcsk9特异性的结合蛋白mv072及其应用 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| CA3031542A1 (en) * | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
| US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
| CN116640214A (zh) | 2016-08-09 | 2023-08-25 | 科马布有限公司 | 分离抗体及其应用 |
| WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| WO2018054240A1 (en) * | 2016-09-20 | 2018-03-29 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pcsk9 antibodies |
| EP3515950A4 (en) | 2016-09-20 | 2020-10-28 | Wuxi Biologics Ireland Limited. | NEW ANTI-PCSK9 ANTIBODIES |
| WO2018067987A1 (en) | 2016-10-06 | 2018-04-12 | Amgen Inc. | Reduced viscosity protein pharmaceutical formulations |
| WO2018075621A1 (en) * | 2016-10-19 | 2018-04-26 | Vanderbilt University | Human orthopoxvirus antibodies and methods of use therefor |
| WO2018075792A1 (en) | 2016-10-20 | 2018-04-26 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| JOP20190112A1 (ar) | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
| CN108239150A (zh) * | 2016-12-24 | 2018-07-03 | 信达生物制药(苏州)有限公司 | 抗pcsk9抗体及其用途 |
| JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
| CN107698680B (zh) * | 2017-01-22 | 2019-03-01 | 北京东方百泰生物科技有限公司 | 抗pcsk9单克隆抗体 |
| CN108424457B (zh) * | 2017-02-13 | 2021-06-01 | 成都金洛克锶生物技术有限公司 | 针对pcsk9抗体与检测试剂盒的制备及其用途 |
| JP7280189B2 (ja) | 2017-02-17 | 2023-05-23 | アムジエン・インコーポレーテツド | 薬物送達装置用の挿入機構 |
| AU2018220538B2 (en) | 2017-02-17 | 2023-12-14 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
| JP2020508803A (ja) | 2017-03-06 | 2020-03-26 | アムジエン・インコーポレーテツド | 作動防止特徴部を備える薬物送達デバイス |
| KR102627069B1 (ko) | 2017-03-07 | 2024-01-18 | 암겐 인코포레이티드 | 과압에 의한 바늘 삽입 |
| JP2020509837A (ja) | 2017-03-09 | 2020-04-02 | アムジエン・インコーポレーテツド | 薬剤送達装置のための挿入機構 |
| LT3600491T (lt) | 2017-03-28 | 2023-10-10 | Amgen Inc. | Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas |
| US9989519B1 (en) * | 2017-05-04 | 2018-06-05 | Clayton Pharmaceuticals, LLC | Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD) |
| MX2019014615A (es) | 2017-06-08 | 2020-02-07 | Amgen Inc | Dispositivo de administracion de farmacos accionado por par de torsion. |
| US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| TW202310872A (zh) * | 2017-06-09 | 2023-03-16 | 法商賽諾菲生物技術公司 | 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法 |
| US20190031774A1 (en) | 2017-06-09 | 2019-01-31 | Sanofi Biotechnology | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| EP3641857A1 (en) | 2017-06-22 | 2020-04-29 | Amgen Inc. | Device activation impact/shock reduction |
| EP3641861A1 (en) | 2017-06-23 | 2020-04-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
| KR102659791B1 (ko) | 2017-07-06 | 2024-04-23 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
| IL271173B2 (en) | 2017-07-21 | 2024-04-01 | Amgen Inc | Gas permeable sealing element for drug container and methods of assembly |
| WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF |
| JP2020528296A (ja) | 2017-07-25 | 2020-09-24 | アムジエン・インコーポレーテツド | ギヤモジュールを有する薬物送達デバイス及び関連する組立方法 |
| EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
| EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
| EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
| MA50348A (fr) | 2017-10-09 | 2020-08-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé |
| WO2019090086A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
| US20200338271A1 (en) | 2017-11-06 | 2020-10-29 | Amgen Inc. | Fill-finish assemblies and related methods |
| EP3706830A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Drug delivery device with placement and flow sensing |
| CN111225696B (zh) | 2017-11-10 | 2023-07-18 | 安进公司 | 用于药物递送装置的柱塞 |
| MX2020005066A (es) | 2017-11-16 | 2020-08-20 | Amgen Inc | Autoinyector con deteccion de detencion y punto final. |
| SG11202003004RA (en) | 2017-11-16 | 2020-04-29 | Amgen Inc | Door latch mechanism for drug delivery device |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| KR20200103728A (ko) | 2017-12-22 | 2020-09-02 | 리제너론 파마슈티칼스 인코포레이티드 | 약물 제품 불순물 특성화를 위한 시스템 및 방법 |
| WO2019152599A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use |
| AU2019215363A1 (en) | 2018-01-31 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| US11957745B2 (en) | 2018-02-22 | 2024-04-16 | Vanderbilt University | Human Japanese Encephalitis Virus antibodies and methods of use therefor |
| WO2019168774A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| JP7426940B2 (ja) | 2018-03-06 | 2024-02-02 | サノフィ・バイオテクノロジー | 心血管リスクを低減するためのｐｃｓｋ９阻害剤の使用 |
| ES2969882T3 (es) | 2018-03-19 | 2024-05-23 | Regeneron Pharma | Ensayos y reactivos de electroforesis capilar en microchip |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| WO2020010079A2 (en) | 2018-07-02 | 2020-01-09 | Amgen Inc. | Anti-steap1 antigen-binding protein |
| US20210128844A1 (en) | 2018-07-24 | 2021-05-06 | Amgen Inc. | Delivery devices for administering drugs |
| WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
| WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
| CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
| CA3100035A1 (en) | 2018-08-27 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| EA202190032A1 (ru) | 2018-08-30 | 2021-03-12 | Ридженерон Фармасьютикалз, Инк. | Способы определения характеристик белковых комплексов |
| CN110872353B (zh) * | 2018-09-03 | 2021-05-04 | 深圳华大基因科技有限公司 | 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用 |
| AU2019347710A1 (en) | 2018-09-24 | 2021-02-04 | Amgen Inc. | Interventional dosing systems and methods |
| EP3856283A1 (en) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| WO2020072577A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
| MA53818A (fr) | 2018-10-05 | 2022-01-12 | Amgen Inc | Dispositif d'administration de médicament ayant un indicateur de dose |
| EA202191037A1 (ru) | 2018-10-15 | 2021-08-05 | Эмджен Инк. | Устройство доставки лекарственного средства, имеющее демпферный механизм |
| EP3866889A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Platform assembly process for drug delivery device |
| AU2019369498A1 (en) * | 2018-10-31 | 2021-05-20 | Delinia, Inc. | Multivalent regulatory T cell modulators |
| CN111110841A (zh) * | 2018-10-31 | 2020-05-08 | 上海君实生物医药科技股份有限公司 | 含有抗pcsk9抗体的稳定制剂 |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
| US20220031939A1 (en) | 2018-11-01 | 2022-02-03 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| WO2020150491A1 (en) | 2019-01-16 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
| CN109734813B (zh) * | 2019-01-28 | 2022-06-17 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
| AU2020263289A1 (en) | 2019-04-24 | 2021-09-16 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
| JP2022532503A (ja) | 2019-05-13 | 2022-07-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された競合的リガンド結合アッセイ |
| CA3139943A1 (en) | 2019-05-17 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Genome-based methods for reducing cardiovascular risk |
| EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
| EP4034870A1 (en) | 2019-09-24 | 2022-08-03 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| WO2021058597A1 (en) | 2019-09-24 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject is at risk of developing arterial plaques |
| KR20220104797A (ko) | 2019-11-25 | 2022-07-26 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 에멀전을 이용한 지속 방출 제형 |
| CN115066272A (zh) | 2019-12-10 | 2022-09-16 | 再生元制药公司 | Pcsk9抑制剂治疗纯合家族性高胆固醇血症的用途 |
| WO2021150558A1 (en) | 2020-01-21 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| WO2022031882A1 (en) * | 2020-08-06 | 2022-02-10 | Stelexis Therapeutics, Llc | Il-8 antibodies and methods of use thereof |
| AU2021332355A1 (en) | 2020-08-31 | 2023-03-23 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| US20220160828A1 (en) | 2020-11-25 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| EP4262757A1 (en) | 2020-12-17 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| US20220228107A1 (en) | 2021-01-20 | 2022-07-21 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| CA3207883A1 (en) | 2021-03-03 | 2022-09-09 | Xiaobin Xu | Systems and methods for quantifying and modifying protein viscosity |
| JP2024519407A (ja) | 2021-03-26 | 2024-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 混合プロトコルを作成するための方法およびシステム |
| US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
| AU2022279223A1 (en) | 2021-05-21 | 2023-10-19 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
| WO2022256383A1 (en) | 2021-06-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| AU2022307659A1 (en) | 2021-07-05 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Utilization of antibodies to shape antibody responses to an antigen |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| IL311527A (en) | 2021-09-20 | 2024-05-01 | Regeneron Pharma | Methods for controlling antibody heterogeneity |
| WO2023059800A2 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| CN118076885A (zh) | 2021-10-07 | 2024-05-24 | 里珍纳龙药品有限公司 | pH计校准与校正 |
| CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
| WO2024040020A1 (en) | 2022-08-15 | 2024-02-22 | Absci Corporation | Quantitative affinity activity specific cell enrichment |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| US5399670A (en) | 1992-04-30 | 1995-03-21 | Alpha Therapeutic Corporation | Solubilization and stabilization of factor VIII complex |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Ｖｅｇｆ結合性ポリペプチド |
| EP0797999A3 (en) | 1996-03-26 | 2002-09-25 | Eli Lilly And Company | Formulations of obesity protein |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US20070224663A1 (en) | 1997-03-07 | 2007-09-27 | Human Genome Sciences, Inc. | Human Secreted Proteins |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CA2317411C (en) | 1998-01-30 | 2005-06-28 | Scios Inc. | Controlled release delivery of peptide or protein |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| EP1514933A1 (en) | 1999-07-08 | 2005-03-16 | Research Association for Biotechnology | Secretory protein or membrane protein |
| US7129338B1 (en) | 1999-07-08 | 2006-10-31 | Research Association For Biotechnology | Secretory protein or membrane protein |
| US7029895B2 (en) | 1999-09-27 | 2006-04-18 | Millennium Pharmaceuticals, Inc. | 27411, a novel human PGP synthase |
| CA2399727A1 (en) | 2000-02-07 | 2001-08-09 | Millennium Pharmaceuticals, Inc. | Narc-1, subtilase-like homologs |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JP2004524005A (ja) | 2000-09-08 | 2004-08-12 | マサチューセッツ インスティテュート オブ テクノロジー | Ｇ−ｃｓｆアナログ組成物および方法 |
| ES2332402T5 (es) | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ，インコーポレイティド | ＩｇＧ抗体の安定な凍結乾燥医薬製剤 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| SI2335725T1 (sl) | 2003-04-04 | 2017-01-31 | Genentech, Inc. | Visokokoncentrirane formulacije protiteles in proteinov |
| EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US20060147945A1 (en) | 2005-01-06 | 2006-07-06 | Edmonds Brian T | Novel secreted proteins and their uses |
| JP5731115B2 (ja) | 2006-05-05 | 2015-06-10 | アイシス ファーマシューティカルズ， インコーポレーテッド | 遺伝子発現を調節するための化合物および方法 |
| ES2366973T3 (es) | 2006-05-05 | 2011-10-27 | Isis Pharmaceuticals, Inc. | Compuestos y procedimiento para modular la expresión génica. |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| ES2406764T3 (es) | 2006-06-16 | 2013-06-10 | Regeneron Pharmaceuticals, Inc. | Formulaciones que comprenden antagonistas de VEGF para administración intravítrea |
| US7572618B2 (en) * | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2008063382A2 (en) | 2006-11-07 | 2008-05-29 | Merck & Co., Inc. | Antagonists of pcsk9 |
| US20100040610A1 (en) | 2006-11-07 | 2010-02-18 | Ayesha Sitlani | Antagonists of pcsk9 |
| US20100150937A1 (en) | 2006-11-07 | 2010-06-17 | Sparrow Carl P | Antagonists of pcsk9 |
| WO2008057457A2 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| AU2007325767A1 (en) | 2006-11-27 | 2008-06-05 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| TW200906439A (en) | 2007-04-13 | 2009-02-16 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| WO2008138536A2 (en) | 2007-05-15 | 2008-11-20 | F. Hoffmann-La Roche Ag | Antibody directed to g protein coupled receptors (gpcr) |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US20100286021A1 (en) | 2007-09-25 | 2010-11-11 | Qun-Yong Zhou | Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders |
| JP2011501952A (ja) * | 2007-10-26 | 2011-01-20 | シェーリング コーポレイション | 脂質障害およびコレステロール障害を治療するための抗ｐｃｓｋ９および方法 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| KR20220162801A (ko) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| ES2658596T3 (es) | 2008-09-19 | 2018-03-12 | Pfizer Inc. | Formulación líquida estable de anticuerpos |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US8748115B2 (en) | 2008-12-12 | 2014-06-10 | Merck Sharp & Dohme Corp. | PCSK9 immunoassay |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| US8357371B2 (en) | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| SG174258A1 (en) | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
| JP2012530721A (ja) | 2009-06-18 | 2012-12-06 | ワイス・エルエルシー | 小モジュール免疫薬のための凍結乾燥製剤 |
| WO2011028938A1 (en) | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
| WO2011037791A1 (en) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonists of pcsk9 |
| WO2011039578A1 (en) | 2009-10-02 | 2011-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event |
| AU2010313381A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX1 and AX189 PCSK9 antagonists and variants |
| CN102639150A (zh) | 2009-10-30 | 2012-08-15 | 默沙东公司 | Ax213和ax132 pcsk9拮抗剂和变体 |
| MY165614A (en) | 2009-11-20 | 2018-04-18 | Biocon Ltd | Formulations of antibody |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| MX2012010481A (es) | 2010-03-11 | 2012-10-09 | Rinat Neuroscience Corp | Anticuerpos con union de antigenos dependiente del ph. |
| GB201005005D0 (en) | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
| WO2012044999A2 (en) * | 2010-10-01 | 2012-04-05 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
| EA028945B1 (ru) | 2010-10-06 | 2018-01-31 | Ридженерон Фармасьютикалз, Инк. | СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К АЛЬФА РЕЦЕПТОРУ ЧЕЛОВЕЧЕСКОГО ИНТЕРЛЕЙКИНА-4 (hIL-4Rα) |
| WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
| CN103328514B (zh) | 2010-11-09 | 2015-12-02 | 阿尔蒂单抗治疗公司 | 用于抗原结合的蛋白复合物及其使用方法 |
| US8771696B2 (en) * | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| WO2012088313A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
| CN103476796A (zh) | 2011-01-28 | 2013-12-25 | 赛诺菲 | 治疗特定受试者组的方法中使用的针对pcsk9的人抗体 |
| BR112013020402A2 (pt) | 2011-02-11 | 2018-09-25 | Irm Llc | antagonistas pcsk9 |
| AR088782A1 (es) | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20140004122A1 (en) | 2011-05-10 | 2014-01-02 | Amgen Inc. | Methods for treating or preventing cholesterol related disorders |
| EP2731623A1 (en) | 2011-07-14 | 2014-05-21 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| EP3536712B1 (en) | 2011-09-16 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
| US9663825B2 (en) | 2012-04-19 | 2017-05-30 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| CN107243078A (zh) | 2012-05-25 | 2017-10-13 | 克塔巴西斯制药有限公司 | 使前蛋白转化酶枯草溶菌素/kexin 9型（pcsk9）减少的方法 |
| AU2013302925B2 (en) * | 2012-08-13 | 2018-07-05 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
| EP2703009A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| EP2703008A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Human antibodies to PCSK9 for use in methods of treating particular groups of subjects |
| EP2706070A1 (en) | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TWI682780B (zh) | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
| EA201592267A1 (ru) | 2013-06-07 | 2016-04-29 | Ридженерон Фармасьютикалз, Инк. | Способы ингибирования атеросклероза посредством введения ингибитора pcsk9 |
| US20150140002A1 (en) | 2013-10-11 | 2015-05-21 | Sanofi | Use of a pcsk9 inhibitor to treat hyperlipidemia |
| AU2014348765A1 (en) | 2013-11-12 | 2016-06-09 | Regeneron Pharmaceuticals, Inc. | Dosing regimens for use with PCSK9 inhibitors |
| US8883157B1 (en) * | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9034332B1 (en) * | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| JP2017506626A (ja) | 2014-02-14 | 2017-03-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法 |
| CN114558129A (zh) | 2014-03-17 | 2022-05-31 | 赛诺菲生物技术公司 | 用于降低心血管风险的方法 |
| US20150283236A1 (en) | 2014-03-17 | 2015-10-08 | Marie Baccara-Dinet | Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled |
| PL3169362T3 (pl) | 2014-07-16 | 2020-12-28 | Sanofi Biotechnology | Sposoby leczenia pacjentów wysokiego ryzyka sercowo-naczyniowego z hipercholesterolemią |
| JP2017528427A (ja) | 2014-07-16 | 2017-09-28 | サノフィ・バイオテクノロジー | ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法 |
| CN107922507B (zh) | 2015-08-18 | 2022-04-05 | 瑞泽恩制药公司 | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 |
| US10933134B2 (en) | 2017-03-16 | 2021-03-02 | Memorial Sloan Kettering Cancer Center | Combination therapies for treatment of cancer |
-
2009
- 2009-12-14 JO JOP/2009/0481A patent/JO3672B1/ar active
- 2009-12-15 HR HRP20170488TT patent/HRP20170488T4/hr unknown
- 2009-12-15 CA CA2747123A patent/CA2747123C/en active Active
- 2009-12-15 MX MX2011006197A patent/MX2011006197A/es active IP Right Grant
- 2009-12-15 US US12/637,942 patent/US8062640B2/en active Active
- 2009-12-15 AU AU2009333326A patent/AU2009333326B9/en active Active
- 2009-12-15 DK DK09793408.7T patent/DK2358756T4/da active
- 2009-12-15 ES ES16200305T patent/ES2898661T3/es active Active
- 2009-12-15 NZ NZ593155A patent/NZ593155A/xx unknown
- 2009-12-15 HU HUE09793408A patent/HUE032681T2/en unknown
- 2009-12-15 UY UY0001032329A patent/UY32329A/es not_active Application Discontinuation
- 2009-12-15 ME MEP-2011-111A patent/ME01327B/me unknown
- 2009-12-15 BR BRPI0922885-3A patent/BRPI0922885B1/pt active IP Right Grant
- 2009-12-15 HR HRP20211688TT patent/HRP20211688T1/hr unknown
- 2009-12-15 LT LTEP16200305.7T patent/LT3156422T/lt unknown
- 2009-12-15 RU RU2011129316A patent/RU2552169C3/ru active Protection Beyond IP Right Term
- 2009-12-15 JP JP2011540965A patent/JP5318965B2/ja active Active
- 2009-12-15 MX MX2014004581A patent/MX341041B/es unknown
- 2009-12-15 KR KR1020157001056A patent/KR101699707B1/ko active IP Right Grant
- 2009-12-15 EP EP16200305.7A patent/EP3156422B1/en active Active
- 2009-12-15 WO PCT/US2009/068013 patent/WO2010077854A1/en active Application Filing
- 2009-12-15 PT PT162003057T patent/PT3156422T/pt unknown
- 2009-12-15 PE PE2011001214A patent/PE20120014A1/es active IP Right Grant
- 2009-12-15 SI SI200931637T patent/SI2358756T2/sl unknown
- 2009-12-15 NZ NZ601923A patent/NZ601923A/xx unknown
- 2009-12-15 PT PT97934087T patent/PT2358756T/pt unknown
- 2009-12-15 KR KR1020117013676A patent/KR101504494B1/ko active IP Right Grant
- 2009-12-15 ME MEP-2017-70A patent/ME02760B/me unknown
- 2009-12-15 EP EP09793408.7A patent/EP2358756B2/en active Active
- 2009-12-15 RS RS20170255A patent/RS55771B2/sr unknown
- 2009-12-15 RS RS20211437A patent/RS62580B1/sr unknown
- 2009-12-15 EP EP21185555.6A patent/EP3943510A3/en active Pending
- 2009-12-15 ES ES09793408T patent/ES2613489T5/es active Active
- 2009-12-15 CN CN201410749251.XA patent/CN104447997A/zh active Pending
- 2009-12-15 PL PL16200305T patent/PL3156422T3/pl unknown
- 2009-12-15 RU RU2015109166A patent/RU2697773C2/ru active
- 2009-12-15 UA UAA201108829A patent/UA105650C2/ru unknown
- 2009-12-15 DK DK16200305.7T patent/DK3156422T3/da active
- 2009-12-15 PA PA20098854201A patent/PA8854201A1/es unknown
- 2009-12-15 SI SI200932149T patent/SI3156422T1/sl unknown
- 2009-12-15 PL PL09793408.7T patent/PL2358756T5/pl unknown
- 2009-12-15 LT LTEP09793408.7T patent/LT2358756T/lt unknown
- 2009-12-15 HU HUE16200305A patent/HUE056244T2/hu unknown
- 2009-12-15 TW TW098142896A patent/TWI465249B/zh active
- 2009-12-15 AR ARP090104880A patent/AR077724A1/es active IP Right Grant
- 2009-12-15 CN CN200980150206.XA patent/CN102245641B/zh active Active
-
2010
- 2010-11-19 US US12/949,846 patent/US8501184B2/en active Active
-
2011
- 2011-05-22 IL IL213050A patent/IL213050A/en active IP Right Grant
- 2011-05-23 ZA ZA2011/03762A patent/ZA201103762B/en unknown
- 2011-06-02 CR CR20110296A patent/CR20110296A/es unknown
- 2011-06-06 NI NI201100111A patent/NI201100111A/es unknown
- 2011-06-13 TN TN2011000300A patent/TN2011000300A1/fr unknown
- 2011-06-13 DO DO2011000184A patent/DOP2011000184A/es unknown
- 2011-06-14 CO CO11073672A patent/CO6571847A2/es active IP Right Grant
- 2011-06-14 HN HN2011001659A patent/HN2011001659A/es unknown
- 2011-06-15 EC EC2011011134A patent/ECSP11011134A/es unknown
-
2012
- 2012-11-30 US US13/690,585 patent/US20130085266A1/en not_active Abandoned
-
2013
- 2013-04-19 JP JP2013088230A patent/JP5902122B2/ja active Active
-
2014
- 2014-02-02 IL IL230771A patent/IL230771A/en active IP Right Grant
-
2015
- 2015-06-12 US US14/737,488 patent/US9550837B2/en active Active
-
2016
- 2016-12-13 US US15/377,364 patent/US10023654B2/en active Active
-
2017
- 2017-03-10 CY CY20171100308T patent/CY1118896T1/el unknown
- 2017-06-16 NL NL300879C patent/NL300879I2/nl unknown
- 2017-06-19 CY CY2017021C patent/CY2017021I1/el unknown
- 2017-06-19 LT LTPA2017019C patent/LTC2358756I2/lt unknown
- 2017-06-21 LU LU00024C patent/LUC00024I2/en unknown
- 2017-06-21 FR FR17C1022C patent/FR17C1022I2/fr active Active
- 2017-06-27 HU HUS1700029C patent/HUS1700029I1/hu unknown
- 2017-06-27 NO NO2017029C patent/NO2017029I2/no unknown
- 2017-07-03 FI FIEP09793408.7T patent/FI2358756T4/fi active
- 2017-07-03 FI FIC20170031C patent/FIC20170031I1/fi unknown
-
2018
- 2018-06-04 US US15/996,773 patent/US10941210B2/en active Active
-
2021
- 2021-01-28 US US17/160,634 patent/US20210253735A1/en not_active Abandoned
-
2023
- 2023-04-05 US US18/296,265 patent/US20230340153A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2552169C3 (ru) | Высокоаффинные человеческие антитела к pcsk9 | |
| JP6400471B2 (ja) | 抗ａｎｇｐｔｌ３抗体及びその使用 | |
| JP2019513751A5 (ru) | ||
| RU2376316C2 (ru) | Человеческие антитела против человеческого 4-1вв (cd137) | |
| HRP20170524T1 (hr) | Humana protutijela koja vežu humani protein 4 nalik angiopoietinu | |
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| RU2008119689A (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| RU2009147744A (ru) | Профилактика и лечение патологических состояний глаз, вызванных комплементом | |
| JP2010526028A5 (ru) | ||
| RU2008137764A (ru) | Способы предотвращения и лечения амилоидных заболеваний | |
| RU2430111C3 (ru) | Молекулы антител с улучшенными свойствами | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения | |
| TW200720289A (en) | Antibodies against CCR5 and uses thereof | |
| UA113728C2 (xx) | Фармацевтична композиція, яка містить антитіло до pcsk9 людини | |
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2008514730A5 (ru) | ||
| FI3416684T3 (fi) | Menetelmiä ateroskleroosin hoitamiseksi tai ehkäisemiseksi antamalla ANGPTL3:n inhibiittoria | |
| RU2012136817A (ru) | СПОСОБЫ ЛЕЧЕНИЯ ДИАБЕТА АНТАГОНИСТАМИ Dll4 | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| NZ595011A (en) | Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases | |
| RU2011142183A (ru) | Средство для лечения ревматоидного артрита | |
| JP2016530223A5 (ru) | ||
| JP2010527939A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4A | Extension of patent duration |
Effective date: 20180119 |